… The goal of checkpoint inhibitor combination therapy is to improve clinical response and …
In this review, we highlight the rationale, evidence and challenges in designing synergistic …

… immune checkpoint inhibitors, about 30% of them do respond … finally stop responding to
this form of immunotherapy [4,5]. … resistance to immune checkpoint inhibitors needs to meet at …

… -checkpoint inhibitors (ICIs) can provide durable responses and … setting have adopted
pathological response as a primary end … Unresolved challenges for the optimal use of ICIs with …

… Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still
constrained by lack of response … biomarkers and toxicities from immune checkpoint inhibitors. …

… -term—even complete—responses, the reality is that still the majority of patients do not benefit
from these treatments. Sometimes it is particularly challenging for physicians to determine …

… , with focus on key endpoints like overall response rate (ORR), progression-free … challenges
associated with ICI therapy in lymphomas, and the strategies to overcome those challenges …

… that drive immune responses and evasion are largely unresolved. Predicting tumor response
and resistance to immune checkpoint inhibitors is a significant challenge. In this review, we …

… specific issues ascribing HCC patients as a challenging population. Anecdotal evidence
showing complete responses from anti-PD-1 … (71) To overcome these numerous challenges, the …

… Thirty‐two patients were enrolled in this study, of whom 19 were evaluated for response
outside the areas treated directly with ablation, and 5 (26.3%; 95% confidence interval, 9.1%–…

… to its ligands, such as PD-L1/PD/L2 (expressed on tumor cells or APCs), an inhibitory signal
turns off the immune response mediated by activated T and NK cells. A2aR is expressed on …